The Food and Drug Administration has done a generally exemplary job of executing its mandate throughout its 118-year modern history. But the federal rescheduling of cannabis, which President Biden recently confirmed is moving forward, will pose unique challenges to FDA regulators.
The plan is to move cannabis from Schedule I, which includes drugs with “no currently accepted medical use,” such as LSD and ecstasy, to the less-dangerous Schedule III category, which includes drugs that have “a moderate to low potential for physical and psychological dependence.”
Click this link for the original source of this article.
Author: Deb Tharp
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.